Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

0.3080 -0.0141 (-4.38%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Stocks That Hit 52-Week Lows On Wednesday

June 30, 2021

During Wednesday's morning session, 29 stocks hit new 52-week lows. Points of Interest: The largest company by market cap to set a new 52-week low was CoStar Gr (...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Earnings Scheduled For May 10, 2021

May 10, 2021

Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Return On Capital Employed Overview: Mersana Therapeutics

June 24, 2021

During Q1, Mersana Therapeutics's (NASDAQ:MRSN) reported sales totaled $11.00 thousand. Despite a 20.35% in earnings, the company posted a loss of $34.61 million. Mersana...

Via Benzinga

Mersana Therapeutics: Return On Capital Employed Insights

June 08, 2021

During Q1, Mersana Therapeutics's (NASDAQ:MRSN) reported sales totaled $11.00 thousand. Despite a 20.35% in earnings, the company posted a loss of $34.61 million. Mersana...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients

April 09, 2021

Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.